Login
$GERN
$0.97 +$0.03 (2.77%) After hours

$GERN SEC Filings

Filed On Filing
16 Nov 2026 Form 4: Semerjian Harout, Director

Bought 53,500 shares ($50.8K)

10 Nov 2026 SCHEDULE 13G
04 Nov 2026 10-Q
04 Nov 2026 8-K: Results of Operations and Financial Condition

Achieved $60.1 million in RYTELO® (imetelstat) net product revenue in Q3 2026, an increase of 5% compared to Q2 2026

28 Oct 2026 8-K: Other Events

FOSTER CITY, Calif., – October 28, 2026 – Geron Corporation (Nasdaq: GERN), a commercial-stage hematology biopharmaceutical company, today announced the decision to discontinue the Phase 3 IMpactMF trial evaluating imetelstat in JAK inhi...

01 Oct 2026 Form 4: Spiegel Robert J., Director

Received 6,351 shares as a grant or award ($7.81K)

14 Aug 2026 SCHEDULE 13G/A
07 Aug 2026 SCHEDULE 13G
06 Aug 2026 8-K: Results of Operations and Financial Condition

Achieved $57.5 million in RYTELO® (imetelstat) net product revenue in Q2 2026, an increase of 11% compared to Q1 2026

05 Aug 2026 10-Q
05 Aug 2026 S-8
01 Jul 2026 Form 4: Spiegel Robert J., Director

Received 6,103 shares as a grant or award ($7.81K)

27 May 2026 8-K: Departure/Election of Directors or Officers; Compensation; Submission of Matters to a Vote of Security Holders

Successor to and Continuation of Prior Plans. The Plan is intended as the successor to and continuation of the Geron Corporation 2011 Incentive Award Plan (the “2011 Plan”) and the Geron Corporation 1992 Stock Option Plan (the “1992 Plan...

26 May 2026 Form 4: Spiegel Robert J., Director

Granted 220,000 Stock Option (right to buy)

26 May 2026 Form 4: O'Farrell Elizabeth G., Director

Granted 220,000 Stock Option (right to buy)

26 May 2026 Form 4: Molineaux Susan, Director

Granted 220,000 Stock Option (right to buy)

26 May 2026 Form 4: McDonald John F, Director

Granted 220,000 Stock Option (right to buy)

26 May 2026 Form 4: Bir Dawn Carter, Director

Granted 220,000 Stock Option (right to buy)

15 May 2026 SCHEDULE 13G/A
08 May 2026 SCHEDULE 13G/A

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support